Irinotecan Hydrochloride Accord Healthcare Ireland (Irinotecan Hydrochloride Trihydrate)

After administration, Irinotecan is metabolised to SN‑38, which binds to the DNA‑topoisomerase I complex and prevents the re‑ligation of single‑strand DNA breaks. This disruption of DNA replication triggers cell death, particularly in rapidly dividing cancer cells.

The dose of Irinotecan is determined individually by the prescribing oncologist based on factors such as the patient’s body surface area, treatment regimen, and clinical condition. No standard dosing information is provided here; the prescriber sets the appropriate regimen.

Irinotecan is classified as contraindicated in pregnancy and breastfeeding because it can cause fetal harm and is excreted in breast milk. Women of child‑bearing potential should use effective contraception, and lactating mothers should avoid the drug.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, whereas alternatives such as oxaliplatin are platinum‑based agents. Irinotecan is often used when tumors are resistant to fluoropyrimidines or as part of combination regimens, offering a different mechanism of action that can overcome certain drug‑resistance patterns.

Irinotecan injectable solution must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. It should be kept in its original packaging until ready for use to maintain stability and potency.

Irinotecan is given as an intravenous infusion, usually over 30‑90 minutes depending on the protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with appropriate monitoring for infusion‑related reactions.

The most serious risks include severe neutropenia with infection, febrile neutropenia, and life‑threatening diarrhea or colitis. Prompt medical attention is required if patients develop fever, persistent diarrhea, or signs of infection during treatment.

Irinotecan should be avoided in patients with known hypersensitivity to the drug or its components, those with uncontrolled bowel obstruction, severe hepatic impairment, or in pregnant and breastfeeding women. Clinicians must assess each patient’s medical history before initiating therapy.